Prescribing information (external link)
Dr Stephen K.L. Chia – How important is it to balance progression-free survival and maintaining quality of life in patients with visceral metastases?
Indications:1
Advanced breast cancer (aBC)
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).
In pre-/perimenopausal women, the ET should be combined with an LHRH agonist
KISQALI is not recommended to be used in combination with tamoxifen.
For more safety information, click here. For the full safety profile, please refer to the KISQALI Summary of Product Characteristics.
The efficacy and safety profile of KISQALI has not been studied in patients with critical visceral disease.1
Click the play button below to watch the video from Dr Stephen K.L. Chia
Join Dr Chia as he shares insights on balancing the treatment goals of HR+/HER2− aBC patients with visceral metastases.
Explore the efficacy outcomes in patients treated with KISQALI + ET
Learn more about the QoL data in patients treated with KISQALI + ET
aBC, advanced breast cancer; AI, aromatase inhibitor; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; QoL, quality of life.
Reference
KISQALI® (ribociclib) Summary of Product Characteristics.
UK | May 2026| FA-11645994
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
